NCT04278144 2025-09-15A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc.Phase 1/2 Terminated175 enrolled
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT04570839 2024-07-18COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.Compugen LtdPhase 1/2 Completed48 enrolled
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts